Tumor Cell Nanovaccines Based on Genetically Engineered Antibody‐Anchored Membrane

Abstract excerpt

Despite the promise in whole-tumor cell vaccines, a key challenge is to overcome the lack of costimulatory signals. Here, agonistic-antibody-boosted tumor cell nanovaccines are reported by genetically engineered antibody-anchored membrane (AAM) technology, capable of effectively activating costimulatory pathways. Specifically, the AAM can be stably constructed following genetic engineering of tumor cell membranes...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Advanced biosensing and bioanalysis techniques
• Share to Monoclonal and Polyclonal Antibodies Research